← brief for 2026-08-13 · Transplant & xeno

Sequential HER2-targeted antibody-drug conjugate therapy for acquired resistance in a 55-year-old male kidney transplant recipient with metastatic urothelial carcinoma: a case report.

Article B Peer reviewed Small trial

Key takeaways

A case report of a 55-year-old with metastatic urothelial carcinoma using sequential antibody-drug conjugate therapy. This group had no prior kidney disease.

Who did this work

Li T · Zhang Y · Liu G · Chen J · Zhang S · Sun M

Source

Article · PubMed, CKD severity and reversal · 2026 Jun 24
https://pubmed.ncbi.nlm.nih.gov/42591779/